{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:55:32Z","timestamp":1781567732583,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Tokyo University of Science"},{"name":"Enago"},{"name":"Research Education Fund"},{"name":"Tokyo University of Science"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genomics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ygeno.2018.12.012","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T19:50:34Z","timestamp":1545421834000},"page":"1889-1895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells"],"prefix":"10.1016","volume":"111","author":[{"given":"Yoko","family":"Ogino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2239-6208","authenticated-orcid":false,"given":"Akira","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Uchiumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei-ichi","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygeno.2018.12.012_bb0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0010","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1021\/jm4001049","article-title":"Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors","volume":"56","author":"Galli","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer","volume":"151","author":"Sampath","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2016.10.027","article-title":"NAD+ salvage pathway in cancer metabolism and therapy","volume":"114","author":"Kennedy","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0025","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2174\/1389203717666160419150014","article-title":"New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase","volume":"17","author":"Tanuma","year":"2016","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0030","doi-asserted-by":"crossref","first-page":"e1052180","DOI":"10.1080\/23723556.2015.1052180","article-title":"New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology","volume":"3","author":"Roulston","year":"2016","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0035","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","volume":"26","author":"Holen","year":"2008","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0045","first-page":"5751","article-title":"CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo","volume":"59","author":"Hjarnaa","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0050","first-page":"2843","article-title":"A Phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","article-title":"Anticancer agent CHS-828 inhibits cellular synthesis of NAD","volume":"367","author":"Olesen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0060","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-009-1125-3","article-title":"Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data","volume":"65","author":"von Heideman","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0065","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/cbic.201402023","article-title":"Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase","volume":"15","author":"Oh","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0070","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/cb500347p","article-title":"NAMPT is the cellular target of STF-31-like small-molecule probes","volume":"9","author":"Adams","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0075","article-title":"Structural basis for resistance to diverse classes of NAMPT inhibitors","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0080","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/1471-2407-10-677","article-title":"Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase","volume":"10","author":"Olesen","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0090","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.18632\/oncotarget.24731","article-title":"Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment","volume":"9","author":"Ogino","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.apradiso.2015.08.001","article-title":"Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells","volume":"106","author":"Sato","year":"2015","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0100","doi-asserted-by":"crossref","first-page":"18231","DOI":"10.1038\/srep18231","article-title":"A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation","volume":"5","author":"Fujimori","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/CAD.0000000000000519","article-title":"Role of the uridine\/cytidine kinase 2 mutation in cellular sensitiveness toward 3'-ethynylcytidine treatment of human cancer cells","volume":"28","author":"Sato","year":"2017","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygeno.2018.12.012_bb0110","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/jm4008664","article-title":"Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors","volume":"56","author":"Zheng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbrc.2017.07.143","article-title":"Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation","volume":"491","author":"Guo","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2867-5-30","article-title":"ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal","volume":"5","author":"Choi","year":"2005","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0125","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bcp.2011.12.042","article-title":"ABC transporters and their role in nucleoside and nucleotide drug resistance","volume":"83","author":"Fukuda","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0130","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1349-7006.2007.00567.x","article-title":"PolyADP-ribosylation and cancer","volume":"98","author":"Miwa","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0135","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1038\/cddis.2013.133","article-title":"PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways","volume":"4","author":"Shirai","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ygeno.2018.12.012_bb0140","series-title":"PARP Inhibitors for Cancer Therapy","first-page":"99","article-title":"PARP and carcinogenesis","author":"Wang","year":"2015"}],"container-title":["Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0888754318306633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0888754318306633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:22:02Z","timestamp":1760163722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0888754318306633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0888754318306633"],"URL":"https:\/\/doi.org\/10.1016\/j.ygeno.2018.12.012","relation":{},"ISSN":["0888-7543"],"issn-type":[{"value":"0888-7543","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells","name":"articletitle","label":"Article Title"},{"value":"Genomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygeno.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}